1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Peripheral Neuropathic Pain-Pipeline Insights, 2017


DelveInsight’s, “ Peripheral Neuropathic Pain-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Peripheral Neuropathic Pain. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Peripheral Neuropathic Pain. DelveInsight’s Report also assesses the Peripheral Neuropathic Pain therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of Peripheral Neuropathic Pain
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Peripheral Neuropathic Pain pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Peripheral Neuropathic Pain and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Peripheral Neuropathic Pain-Pipeline Insights, 2017
Illustrative

- Peripheral Neuropathic Pain Overview
- Peripheral Neuropathic Pain Pipeline Therapeutics
- Peripheral Neuropathic Pain Therapeutics under Development by Companies
- Peripheral Neuropathic Pain Filed and Phase III Products
- Comparative Analysis
- Peripheral Neuropathic Pain Phase II Products
- Comparative Analysis
- Peripheral Neuropathic Pain Phase I and IND Filed Products
- Comparative Analysis
- Peripheral Neuropathic Pain Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Peripheral Neuropathic Pain - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Peripheral Neuropathic Pain - Discontinued Products
- Peripheral Neuropathic Pain - Dormant Products
- Companies Involved in Therapeutics Development for Peripheral Neuropathic Pain
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Peripheral Neuropathic Pain, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Peripheral Neuropathic Pain Assessment by Monotherapy Products
- Peripheral Neuropathic Pain Assessment by Combination Products
- Peripheral Neuropathic Pain Assessment by Route of Administration
- Peripheral Neuropathic Pain Assessment by Stage and Route of Administration
- Peripheral Neuropathic Pain Assessment by Molecule Type
- Peripheral Neuropathic Pain Assessment by Stage and Molecule Type
- Peripheral Neuropathic Pain Therapeutics - Discontinued Products
- Peripheral Neuropathic Pain Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Peripheral Neuropathic Pain, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Peripheral Neuropathic Pain Assessment by Monotherapy Products
- Peripheral Neuropathic Pain Assessment by Combination Products
- Peripheral Neuropathic Pain Assessment by Route of Administration
- Peripheral Neuropathic Pain Assessment by Stage and Route of Administration
- Peripheral Neuropathic Pain Assessment by Molecule Type
- Peripheral Neuropathic Pain Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Fibromyalgia  - Market Insights, Epidemiology and Market Forecast-2023

Fibromyalgia  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Fibromyalgia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Neuropathic  Pain - Market Insights, Epidemiology and Market Forecast-2023

Neuropathic  Pain - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Neuropathic Pain - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Global Market Study on Neuropathic Pain: Anticonvulsants Drug Class Segment Projected to Witness the Highest Growth Through 2024

Global Market Study on Neuropathic Pain: Anticonvulsants Drug Class Segment Projected to Witness the Highest Growth Through 2024

  • $ 4900
  • Industry report
  • November 2016
  • by Persistence Market Research

This Persistence Market Research report examines the global neuropathic pain market for the period 2016–2024. The primary objective of the report is to offer updates and information related to market ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.